期刊
CLINICAL MICROBIOLOGY REVIEWS
卷 34, 期 1, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/CMR.00043-19
关键词
cytomegalovirus; antiviral agents; clinical trials; diagnostics; immune monitoring; immunocompromised hosts; transplant infectious diseases; transplantation; vaccines
类别
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [HHSN272201100041C, K24HL093294, HHSN272201600015C]
- Chimerix Inc.
- Gilead Sciences
- Takeda
- Merck
- Astellas
Individuals with compromised immune systems are at the highest risk for complications from CMV infection, including those living with HIV/AIDS, transplant recipients, and fetuses. Despite significant progress in prevention, diagnostics, and treatment, there are challenges in optimal control of CMV infection and disease in transplant settings.
Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据